The Rohatyn Group Completes Investment in Innovative Pet Accessories Company, MyFamily
11.3.2021 21:24:00 EET | Business Wire | Press release
The Rohatyn Group (“TRG”), a global, US-based asset management firm, today announced that it has completed an investment in the specialized pet accessories company MyFamily Srl (“MyFamily” or the “Company”), establishing a partnership with the Company’s founder, Alessandro Borgese, and existing investors including 035 investimenti S.p.A. TRG’s investment will allow MyFamily to accelerate its product rollout and continue expanding its global distribution channels. Terms of the transaction were not disclosed.
Founded in 2011 in Valenza, Italy, MyFamily is a global producer of engravable pet ID tags and tag engraving machines. The Company’s engraving machines are present in approximately 9,000 retail locations in more than 70 countries worldwide. The Company has recently expanded its pet accessories assortment through a unique range of pet collars, leashes and harnesses, including the technology-enabled Memopet collection, which offers a differentiated smart and interactive experience.
“MyFamily is a highly attractive business that provides a unique product offering in the global pet accessories sector. We believe the Company is well positioned to benefit from accelerated premiumization of pet products and deliver strong growth as the global pet accessories market continues to expand,” said TRG’s Colin Clark, Head of the EMEA Private Markets investment team, and Stepan Karpukhin, Managing Director.
TRG’s Harold Chatelus, who will immediately join the Board of Directors of MyFamily, added, “Alessandro Borgese leads a highly qualified and motivated global management team, whose dedication to product innovation is evident in the quality and design leadership of MyFamily’s product portfolio. TRG will actively support the Company’s expansion strategy with the goal of enhancing scale and solidifying global market leadership.”
Nick Rohatyn, CEO of TRG added, “MyFamily is a high-growth business with international access that fits in perfectly with TRG’s global approach. We believe strongly that the Company has the potential to transform the global pet accessories sector thanks to its innovative and technology-forward strategy. Our investment team will seek to leverage our deep knowledge of the pet care industry and positive experience from current portfolio company Pet Network International to assist Alessandro and his talented team in achieving their growth objectives.”
Alessandro Borgese, founder and CEO of MyFamily, commented, “I am tremendously proud of the growth MyFamily has already achieved, particularly over the last two years, as we have transformed our product portfolio, invested greatly in production quality and automation, and expanded our distribution network following the launch of our US subsidiary. TRG’s investment will accelerate the next phase in MyFamily’s development. We look forward to continuing our growth in partnership with The Rohatyn Group and leveraging the team’s expertise.”
About TRG
Founded in 2002, The Rohatyn Group is an emerging markets focused asset management firm headquartered in New York, with a presence around the globe including Boston, Buenos Aires, Montevideo, Lima, São Paulo, San Jose, London, Cairo, Mumbai, New Delhi, Singapore, Hanoi, Kuala Lumpur and Rotorua. For more information, please visit www.rohatyngroup.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005900/en/
Contact information
Julie Rudnick / Columbia Clancy
Sard Verbinnen & Co
(212) 687-8080
JRudnick@SARDVERB.COM / CClancy@SARDVERB.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom